Roche/Ipsen suspend pivotal taspoglutide trials
This article was originally published in Scrip
Executive Summary
Roche and Ipsen have stopped dosing patients in pivotal trials of their GLP-1 analogue taspoglutide, following high patient drop-out rates owing to gastrointestinal tolerability and hypersensitivity reactions. The news – which comes a few months after the companies first disclosed the unexpected hypersensitivity and anaphylactic reactions associated with the injection – has fuelled speculation that the end may be near for the experimental antidiabetic.